Atea Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
Atea Pharmaceuticals, Inc. (AVIR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 2.19 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2026-08-12
- Atea Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2026-06-30 was 351.60K shares, a 14.66% decline year-over-year.
- Atea Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2026-03-31 was 1.83M shares, a 37.48% decline year-over-year.
- Atea Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2025-12-31 was 0.00 shares.
- Atea Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2025-09-30 was 40.80K shares, a 20.00% increase year-over-year.
- Atea Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2025 was 3.39M shares, a 5.37% increase from fiscal 2024.
- Atea Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2024 was 3.21M shares, a 14.93% decline from fiscal 2023.
- Atea Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2023 was 3.78M shares, a 2.76% decline from fiscal 2022.
- Atea Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2022 was 3.88M shares, a 9.09% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month |
|---|---|---|---|---|
| 2026-06-30 | 351.60K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | 2.19M shares 10-Q · filed 2026-08-12 | 2.19M shares derived: sum of 3 quarters · filed 2026-08-12 | 2.23M shares derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 1.83M shares 10-Q · filed 2026-05-12 | 1.83M shares derived: sum of 2 quarters · filed 2026-05-12 | 1.87M shares derived: sum of 3 quarters · filed 2026-05-12 | 2.29M shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 40.80K shares derived: sum of 2 quarters · filed 2026-03-05 | 452.80K shares derived: sum of 3 quarters · filed 2026-03-05 | 3.39M shares 10-K · filed 2026-03-05 |
| 2025-09-30 | 40.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 452.80K shares derived: sum of 2 quarters · filed 2025-11-12 | 3.39M shares 10-Q · filed 2025-11-12 | 3.39M shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | 412.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 3.35M shares 10-Q · filed 2025-08-07 | 3.35M shares derived: sum of 3 quarters · filed 2025-08-07 | 3.38M shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 2.93M shares 10-Q · filed 2025-05-12 | 2.93M shares derived: sum of 2 quarters · filed 2025-05-12 | 2.97M shares derived: sum of 3 quarters · filed 2025-05-12 | 3.21M shares derived: sum of 4 quarters · filed 2025-05-12 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | 34.00K shares derived: sum of 2 quarters · filed 2025-03-06 | 281.20K shares derived: sum of 3 quarters · filed 2025-03-06 | 3.21M shares 10-K · filed 2025-03-06 |
| 2024-09-30 | 34.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 281.20K shares derived: sum of 2 quarters · filed 2024-11-07 | 3.21M shares 10-Q · filed 2024-11-07 | 3.22M shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 247.20K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | 3.18M shares 10-Q · filed 2024-08-07 | 3.19M shares derived: sum of 3 quarters · filed 2024-08-07 | 3.32M shares derived: sum of 4 quarters · filed 2024-08-07 |
| 2024-03-31 | 2.93M shares 10-Q · filed 2024-05-14 | 2.94M shares derived: sum of 2 quarters · filed 2024-05-14 | 3.07M shares derived: sum of 3 quarters · filed 2024-05-14 | 3.41M shares derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-12-31 | 11.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | 136.00K shares derived: sum of 2 quarters · filed 2024-02-28 | 474.50K shares derived: sum of 3 quarters · filed 2024-02-28 | 3.78M shares 10-K · filed 2024-02-28 |
| 2023-09-30 | 125.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | 463.50K shares derived: sum of 2 quarters · filed 2023-11-08 | 3.77M shares 10-Q · filed 2023-11-08 | |
| 2023-06-30 | 338.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 3.64M shares 10-Q · filed 2023-08-08 | ||
| 2023-03-31 | 3.30M shares 10-Q · filed 2023-05-08 | |||
| 2022-12-31 | 3.88M shares 10-K · filed 2023-02-28 | |||
| 2021-12-31 | 3.56M shares 10-K · filed 2022-02-28 | |||
| 2020-12-31 | 1.21M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | 4.61M shares 10-K · filed 2021-03-30 | ||
| 2020-09-30 | 3.41M shares 10-Q · filed 2020-12-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |